New research indicates that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional diet and exercise regimens.
Research printed in a leading medical journal points out that while obese people often shed about a fifth of their body weight while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month after stopping.
"People buying these treatments must be informed of the risk of fast weight regain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a return to original mass within about one and a half years.
Weighing Therapies
The research, which looked at dozens of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with conventional dieting.
Researchers emphasize that people who lose weight through lifestyle changes alone typically experience a less rapid creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Regain
Experts believe the mode of action of the drugs is key to understanding the amplified weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in hunger is no longer kept in check, making binge eating much more probable."
A Chronic Condition?
Health authorities recommend the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, due to the significant potential of weight regain, the treatment is often life-long.
This opinion is reinforced by pharmaceutical companies, who say that the findings "highlight the long-term character of obesity," akin to managing conditions like high blood pressure.
Patient Accounts
Users who have come off the jabs explain a intense return of cravings.
"It was like a trigger activating and you become ravenous," said an individual.
The struggle is exacerbated if individuals have not established permanent lifestyle or habit modifications during therapy.
Growing Interest
Figures show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while the jabs are potent tools for shedding pounds, they are not a standalone fix and long-term success likely depends on combined lifestyle support.
